Intero Biosystems, Inc.
Biotechnology company developing human induced-pluripotent-stem-cell (iPSC)–derived intestinal organoid platforms for preclinical drug discovery and development. Founded in 2024 as a university spin-out, the organization focuses on producing biologically representative miniature human intestines that include multiple supporting cell types to improve translational predictability and reduce reliance on animal-only models.
Industries
N/A
Nr. of Employees
small (1-50)
Products
GastroScreen (iPSC-derived human intestinal organoid platform)
A human intestinal mini-organ system that includes epithelial lining plus supporting tissues (neurons, vasculature, muscle) intended for preclinical safety, efficacy, and disease-modeling studies.
GastroScreen (iPSC-derived human intestinal organoid platform)
A human intestinal mini-organ system that includes epithelial lining plus supporting tissues (neurons, vasculature, muscle) intended for preclinical safety, efficacy, and disease-modeling studies.
Services
Collaborative development of donor-specific or disease-specific intestinal organoid models, including co-culture integrations and custom assay configurations.
Provision of organoid-based testing for safety, toxicology, and efficacy endpoints compatible with imaging, molecular assays, and functional readouts.
Distribution of live or cryopreserved organoid vials delivered ready for experimentation or with defined recovery timelines post-thaw.
Collaborative development of donor-specific or disease-specific intestinal organoid models, including co-culture integrations and custom assay configurations.
Provision of organoid-based testing for safety, toxicology, and efficacy endpoints compatible with imaging, molecular assays, and functional readouts.
Distribution of live or cryopreserved organoid vials delivered ready for experimentation or with defined recovery timelines post-thaw.
Expertise Areas
- Organoid platform development
- iPSC differentiation and culture
- Preclinical drug safety and toxicology testing
- Preclinical efficacy and mechanism-of-action assessment
Key Technologies
- iPSC-derived organoids
- Microphysiological / organ-on-chip-style organoid systems
- Perfusable vascular network formation
- Enteric nervous system and motility assays
News & Updates
Company announced closing of an oversubscribed $2 million pre-seed round to scale production, validate clinical predictability, and build disease models; investors included multiple venture and angel groups.
Awarded first place and over $900,000 in investment prizes at the 2025 Rice Business Plan Competition.
Company CEO selected as a member of the Activate Fellowship’s 2025 cohort, a program that provides funding and entrepreneurship support for deep-tech founders.
Company commentary on recent FDA and NIH policy shifts endorsing New Approach Methodologies (NAMs) and human-relevant models, and the implications for preclinical drug development.
Won first place and received over $900,000 in investment prizes at the 2025 Rice Business Plan Competition.
Company CEO selected for the Activate Fellowship cohort (2025), providing funding and mentorship to accelerate commercialization.
Company announced closing of an oversubscribed $2 million pre-seed round to scale production, validate clinical predictability, and build disease models; investors included multiple venture and angel groups.
Awarded first place and over $900,000 in investment prizes at the 2025 Rice Business Plan Competition.
Company CEO selected as a member of the Activate Fellowship’s 2025 cohort, a program that provides funding and entrepreneurship support for deep-tech founders.
Company commentary on recent FDA and NIH policy shifts endorsing New Approach Methodologies (NAMs) and human-relevant models, and the implications for preclinical drug development.
Won first place and received over $900,000 in investment prizes at the 2025 Rice Business Plan Competition.
Company CEO selected for the Activate Fellowship cohort (2025), providing funding and mentorship to accelerate commercialization.